Bavarian Nordic AS (Bavarian Nordic) is a biotechnology company that specializes in the research, development, and manufacturing of vaccines. The company's business portfolio includes a range of vaccines for public preparedness and travel health. Its public preparedness vaccines include JYNNEOS/IMVAMUNE/IMVANEX for smallpox and monkeypox. The company’s travel health vaccines include Rabipur/RabAvert for rabies, Encepur for tick-borne encephalitis, Vaxchora for cholera, Vivotif for typhoid, and VIMKUNYA for Chikungunya. In 2025, the company delivered more than 10 million vaccine doses to over 40 countries. The company also markets and distributes third-party products. The company's major customers include the Biomedical Advanced Research and Development Authority (BARDA) and the Agence nationale de santé publique FR. The company operates its proprietary commercial-scale manufacturing facility in Kvistgard, Denmark. This facility allows the company to manufacture, analyze, and release sterile vaccines for human use following full EU cGMP requirements. The facility is currently being expanded with a commercial-scale multi-product fill and finish facility for liquid and freeze-dried live viral vaccines. The company has manufactured 28 million doses of smallpox vaccine for the U.S. Strategic National Stockpile and also manufactured 2 million doses of MVA-BN Filo for Janssen as part of their Ebola vaccine regimen. Bavarian Nordic's manufacturing segment is primarily involved in the production of vaccines for various infectious diseases. The segment serves the global healthcare industry, with manufacturing facilities located in Denmark and Switzerland. The company has an operational presence in Hellerup, Denmark; Kvistgard, Denmark; Horsholm, Denmark; Martinsried, Germany; Bern, Switzerland; Durham, North Carolina, USA; and San Diego, California, the US.

- Bavarian Nordic specializes in the research, development, and manufacturing of vaccines based on viral vectors for the delivery of antigens targeting infectious diseases. The company is involved in pioneering research and development with a strong heritage in vaccine development and continues to make innovations to help fight existing and emerging diseases. The R&D unit of Bavarian Nordic is responsible for the research, development, and manufacturing of vaccines, particularly focusing on viral vectors for delivering antigens targeting infectious diseases. The pipeline includes vaccines in clinical development, such as MVA-BN WEV for Equine Encephalitis, which is currently in Phase 2. In FY2025, the company spent DKK780 million on R&D, which, as a percentage of revenue, stood at 12.4% and declined 9.6% YoY.